-
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
Monday, August 7, 2017 - 10:56am | 505Read More...Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine...
-
Getting Into The Business Of Medical Marijuana: An Interview With IGC CEO Ram Mukunda
Wednesday, March 15, 2017 - 6:47am | 1143Read More...Engineering graduate Ram Mukunda spent more than 25 years working in Wall Street. He served in companies communications firms Intelsat SA (NYSE: I) and Startec, before making an incursion into the mining industry through a company he co-founded. India Globalization Capital, Inc. (NYSE: IGC) was...
-
New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys
Friday, February 20, 2015 - 7:22am | 473Read More...According to a recent article in Nature, an experimental drug being tested at the Scripps Research Institute in Florida has been effective in blocking HIV infection in monkeys. The new drug has yet to be tested on humans, but preliminary results in animal testing have researchers excited about...
-
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks
Wednesday, June 18, 2014 - 8:38am | 768Read More...This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...
